Mark Robert Baker, CEO at PROGENICS PHARMACEUTICALS INC (PGNX), bought 369 shares at $9.45 ($3K) on 2012-02-22, disclosed to the SEC on 2012-02-23.
Scheduled purchase ($3k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.40 | 100 | $940 | 27.1% |
| 2 | $9.40 | 166 | $2K | 44.9% |
| 3 | $9.42 | 2 | $19 | 0.5% |
| 4 | $9.45 | 100 | $945 | 27.2% |
| 5 | $9.54 | 1 | $10 | 0.3% |
| Total | $9.41 avg | 369 |
| $3K |
| 100% |
| Filing → |
| PGNX | BUY | 2013-01-23 | $3K | — | Filing → |
| PGNX | BUY | 2012-12-26 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-30 | $3K | — | Filing → |